{"entity":{"type":"insider","cik":"0001485939","url":"/insider/0001485939","json_url":"/insider/0001485939.json","name":"ABERCROMBIE GEORGE B","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":14,"n_filings":14,"first":"2013-03-06","last":"2022-04-20","span_basis":"filed_date"},"name_variants":[{"name":"ABERCROMBIE GEORGE B","source":"filing","n_filings":14,"first_seen":"2013-03-06","last_seen":"2022-04-20"}],"transactions":[{"id":6576995,"accession":"0001127602-22-012272","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-012272","line_url":"/filing/0001127602-22-012272#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":11.04,"price_display":"11.04","price_state":"stated","total_value":55200.0,"total_display":"55,200.00","total_whole":"55,200","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-18","filed_date":"2022-04-20","scope":"insider"},{"id":6151697,"accession":"0001127602-22-005295","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-005295","line_url":"/filing/0001127602-22-005295#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":18.5,"price_display":"18.50","price_state":"stated","total_value":92500.0,"total_display":"92,500.00","total_whole":"92,500","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-15","filed_date":"2022-02-16","scope":"insider"},{"id":5450706,"accession":"0001127602-21-029440","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-029440","line_url":"/filing/0001127602-21-029440#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":12.27,"price_display":"12.27","price_state":"stated","total_value":61350.0,"total_display":"61,350.00","total_whole":"61,350","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-15","filed_date":"2021-11-17","scope":"insider"},{"id":5005103,"accession":"0001127602-21-025496","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-025496","line_url":"/filing/0001127602-21-025496#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":15.06,"price_display":"15.06","price_state":"stated","total_value":75300.0,"total_display":"75,300.00","total_whole":"75,300","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-15","filed_date":"2021-09-17","scope":"insider"},{"id":4592963,"accession":"0001127602-21-025252","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-21-025252","line_url":"/filing/0001127602-21-025252#line-4","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":74000.0,"shares_display":"74,000","price_per_share":15.09,"price_display":"15.09","price_state":"stated","total_value":1116660.0,"total_display":"1,116,660.00","total_whole":"1,116,660","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-10","filed_date":"2021-09-14","scope":"insider"},{"id":4777789,"accession":"0001127602-21-022226","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-022226","line_url":"/filing/0001127602-21-022226#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":15.69,"price_display":"15.69","price_state":"stated","total_value":78450.0,"total_display":"78,450.00","total_whole":"78,450","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-15","filed_date":"2021-07-19","scope":"insider"},{"id":4315857,"accession":"0001127602-21-018061","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-21-018061","line_url":"/filing/0001127602-21-018061#line-2","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6667.0,"shares_display":"6,667","price_per_share":13.9,"price_display":"13.90","price_state":"stated","total_value":92671.3,"total_display":"92,671.30","total_whole":"92,671","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-24","filed_date":"2021-05-26","scope":"insider"},{"id":5213131,"accession":"0001127602-21-016433","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-21-016433","line_url":"/filing/0001127602-21-016433#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":12.7,"price_display":"12.70","price_state":"stated","total_value":88900.0,"total_display":"88,900.00","total_whole":"88,900","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-12","scope":"insider"},{"id":6078152,"accession":"0001567619-18-001672","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-18-001672","line_url":"/filing/0001567619-18-001672#line-2","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Innoviva, Inc.","issuer_ticker":"INVA","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Officer (Sr. VP & Chief Comm. Officer)","role_mark":"O","role_mark_label":"Officer (Sr. VP & Chief Comm. Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP & Chief Comm. Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":14.105,"price_display":"14.10","price_state":"stated","total_value":112840.0,"total_display":"112,840.00","total_whole":"112,840","shares_owned_after":285479.0,"shares_owned_after_display":"285,479","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-21","filed_date":"2018-08-22","scope":"insider"},{"id":6655883,"accession":"0001179110-18-007382","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-18-007382","line_url":"/filing/0001179110-18-007382#line-2","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Innoviva, Inc.","issuer_ticker":"INVA","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Officer (Sr. VP & Chief Comm. Officer)","role_mark":"O","role_mark_label":"Officer (Sr. VP & Chief Comm. Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP & Chief Comm. Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":14.4003,"price_display":"14.40","price_state":"stated","total_value":115202.4,"total_display":"115,202.40","total_whole":"115,202","shares_owned_after":299159.0,"shares_owned_after_display":"299,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-22","scope":"insider"},{"id":6490477,"accession":"0001179110-18-002588","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-18-002588","line_url":"/filing/0001179110-18-002588#line-2","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Innoviva, Inc.","issuer_ticker":"INVA","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Officer (Sr. VP & Chief Comm. Officer)","role_mark":"O","role_mark_label":"Officer (Sr. VP & Chief Comm. Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP & Chief Comm. Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":16.5125,"price_display":"16.51","price_state":"stated","total_value":132100.0,"total_display":"132,100.00","total_whole":"132,100","shares_owned_after":235473.0,"shares_owned_after_display":"235,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-21","filed_date":"2018-02-22","scope":"insider"},{"id":5249591,"accession":"0001179110-17-014574","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-17-014574","line_url":"/filing/0001179110-17-014574#line-2","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Innoviva, Inc.","issuer_ticker":"INVA","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Officer (Sr. VP & Chief Comm. Officer)","role_mark":"O","role_mark_label":"Officer (Sr. VP & Chief Comm. Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP & Chief Comm. Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5215.0,"shares_display":"5,215","price_per_share":13.2589,"price_display":"13.26","price_state":"stated","total_value":69145.1635,"total_display":"69,145.16","total_whole":"69,145","shares_owned_after":258651.0,"shares_owned_after_display":"258,651","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-21","filed_date":"2017-11-22","scope":"insider"},{"id":4293149,"accession":"0001127602-13-031483","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-13-031483","line_url":"/filing/0001127602-13-031483#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":6.19,"price_display":"6.19","price_state":"stated","total_value":18570.0,"total_display":"18,570.00","total_whole":"18,570","shares_owned_after":6000.0,"shares_owned_after_display":"6,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-12","filed_date":"2013-11-13","scope":"insider"},{"id":4720734,"accession":"0001127602-13-009645","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-13-009645","line_url":"/filing/0001127602-13-009645#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001485939","owner_name":"ABERCROMBIE GEORGE B","owner_display_name":"ABERCROMBIE GEORGE B","owner_url":"/insider/0001485939","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":1.23,"price_display":"1.23","price_state":"stated","total_value":3690.0,"total_display":"3,690.00","total_whole":"3,690","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-05","filed_date":"2013-03-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":14,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":14},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000882796","name":"BIOCRYST PHARMACEUTICALS INC","url":"/issuer/0000882796","role":"Director","n_filings":10,"first_seen":"2013-03-06","last_seen":"2022-04-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001080014","name":"Innoviva, Inc.","url":"/issuer/0001080014","role":"Officer (Sr. VP & Chief Comm. Officer)","n_filings":4,"first_seen":"2017-11-22","last_seen":"2018-08-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001485939","retrieved_at":"2026-08-23T14:53:57+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}